afatinib vs Chemotherapy | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
objective response (ORR) | no data | death (overall survival) | no data | progression or death (progression free survival PFS) | no data | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
afatinib vs cisplatin-based chemotherapy | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
objective response (ORR) | no data | death (overall survival) | no data | progression or death (progression free survival PFS) | no data | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
afatinib vs Cisplatin/Pemetrexed | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
objective response (ORR) | no data | death (overall survival) | no data | progression or death (progression free survival PFS) | no data | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
afatinib vs Erlotinib | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
objective response (ORR) | no data | death (overall survival) | no data | progression or death (progression free survival PFS) | no data | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
afatinib vs placebo | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
objective response (ORR) | no data | death (overall survival) | no data | progression or death (progression free survival PFS) | no data | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |